Rybicki said. The 3-D model is important for producing the transplant cosmetically interesting. The researchers said they also used the models in the operating area to increase the surgeons' understanding of the anatomy of the recipient's encounter during the treatment. You can spin, rotate and scroll through as many CT pictures as you desire but there's no substitute for having the true thing in your hands, Dr. Rybicki said. The capability to use the model offers you an unprecedented level of reassurance and self-confidence in the task. Senior surgeons and radiologists mixed up in five face transplantations agreed that the 3-D printed versions provided excellent pre-operative data and allowed complicated anatomy and bony defects to be better appreciated, reducing total procedure time.ARIAD expects to apply for regulatory authorization of ponatinib in the center of next 12 months, providing the prospect of U.S. Advertising authorization by the final end of 2012 or early 2013. Abstracts from the meeting will be accessible online on November 7, 2011 conference. With this trial completely enrolled and all individuals evaluable, data showed an ongoing improvement over time in the anti-leukemic activity and response prices among individuals with chronic-phase CML treated with ponatinib. Further, there were no treatment discontinuations or lack of a major cytogenetic response among chronic-phase patients in the study because the prior data update on the trial in December, 2010.